Clonazepam Orally Disintegrating Tablets, USP, Clonazepam Orally Disintegrating Tablets, USP, JNJ-64407564, JNJ-64407564, Clonazepam Orally Disintegrating Tablets, USP, Pregabalin-ratiopharm® 25 mg Hartkapseln, Pregabalin-ratiopharm® 50 mg Hartkapseln, Clonazepam Orally Disintegrating Tablets, USP, DEXAMETHASONE ELIXIR, USP, Clonazepam Orally Disintegrating Tablets, USP, Clonazepam Orally Disintegrating Tablets, USP
64407564MMY2006
Phase 2 small_molecule active
Quick answer
Clonazepam Orally Disintegrating Tablets, USP, Clonazepam Orally Disintegrating Tablets, USP, JNJ-64407564, JNJ-64407564, Clonazepam Orally Disintegrating Tablets, USP, Pregabalin-ratiopharm® 25 mg Hartkapseln, Pregabalin-ratiopharm® 50 mg Hartkapseln, Clonazepam Orally Disintegrating Tablets, USP, DEXAMETHASONE ELIXIR, USP, Clonazepam Orally Disintegrating Tablets, USP, Clonazepam Orally Disintegrating Tablets, USP for multiple myeloma is a Phase 2 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- multiple myeloma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active